In today’s briefing:
- Samsung Biologics: Post-Offering Trading Dynamics on Potential Overhang
- Innate Immunotherapeutics (ATX AU): 2022 Is Going to Be a Watershed Year
- Venus MedTech (2500.HK) Vs Peijia Medical (9996.HK) Vs CardioFlow (2160.HK) – Dilemma of TAVR Market
Samsung Biologics: Post-Offering Trading Dynamics on Potential Overhang
- Samsung Biologics (207940 KS) has succeeded in a rights offering worth ₩3.2T to the existing shareholders. The subscription rate of the existing shareholders and the ESOP came out at 100.25%.
- The size of immediately floatable shares is estimated at 1 million, representing 1.55% of SO and 22.82x ADTV. It is a size that will significantly impact the short-term flow.
- There is a sufficient circumstantial probability that the 1M new stocks, currently at a 20% return, will lead to immediate profit realization after listing.
Innate Immunotherapeutics (ATX AU): 2022 Is Going to Be a Watershed Year
- Innate Immunotherapeutics (ATX AU) is an Australian pharmaceutical company advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis.
- The company’s primary focus for 2022 is on initiating phase 2 clinical trials in pancreatic cancer and, in the second half of the year in lung fibrosis.
- With latest quarter’s cash burn of AUD0.94 million and cash balance of AUD16.2 million, the company is well-positioned to fund its near-term R&D activities.
Venus MedTech (2500.HK) Vs Peijia Medical (9996.HK) Vs CardioFlow (2160.HK) – Dilemma of TAVR Market
- Even starting late,Peijia took the lead in the number of hospitals entered and sales volume in the 1st year after product launch.It could be a dark horse to achieve corner overtaking.
- The ceiling of China TAVR market is obvious due to high surgery cost and severe shortage of doctors/qualified hospitals. Future price war due to fierce competition is also a concern.
- Related TAVR companies’ high valuation cannot be supported without sufficient incremental markets. So, if companies hope to break the ceiling, they have to develop global markets.
Before it’s here, it’s on Smartkarma
